Empowered Patient Podcast Making Genome Sequencing Accessible to Drive the Future of Personalized Medicine with Allan Sheffield Gene By Gene
Allan Sheffield, Co-Founder of Gene By Gene, offers genetic testing to provide insights into an individual's risk for various diseases, including cancer and rare genetic disorders, allowing for more proactive and preventative healthcare. Analysis of pharmacogenomic data, which examines how an individual's genes influence their response to medications, also helps doctors prescribe the most effective treatments and avoid potential side effects. Integrating genetic data into electronic medical records and using AI to simplify the interpretation of results is enabling doctors and patients to improve patient outcomes, reduce healthcare costs, and use polygenic risk scores to provide more comprehensive insights into an individual's health.
Allan explains, "Gene By Gene is one of the largest genomic sequencing or genetic tech companies in the US, and we do everything from whole genome sequencing to offering hereditary cancer screening, predictive cardiovascular risk, and things like pharmacogenomic testing to see how people respond to different medications. So if you can think about genetic testing, we've got the capabilities to do it."
"We're living in a really exciting time at the moment, where next-generation sequencing, or whole-genome sequencing, is becoming much more of a reality. I think 10 years ago, it would cost over a hundred thousand dollars to sequence your whole genome, which is the 3 billion base pairs of genetic code in your body. And so what we've had to do in the past is do very targeted tests to keep the costs affordable. But with the advancements in technology, we are now doing the whole genome sequence at Gene By Gene for in the hundreds of dollars as opposed to the thousands of dollars. And that's making it much more accessible and much more realistic in healthcare."
#GeneByGene #GeneticTesting #NextGenerationSequencing #NGS #Pharmagenomics #CancerScreening #PredictiveScreening #CardiovascularRisk #PrecisionMedicine